Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
Status:
Active, not recruiting
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared
with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients
with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic
etiology) who already have a CardioMEMs device implanted for non-study related clinical
reasons.